Mesna 200 mg Injection 2 ml belongs to a class of medication known as 'cytoprotectant' primarily used to prevent Hemorrhagic cystitis (a condition that causes bleeding in the urine due to the effect of anticancer agents (Ifosfamide). Our bodies degrade the anticancer drug (ifosfamide) to generate a compound (acrolein) that can injure and irritate the bladder. Mesna 200 mg Injection 2 ml decreases the risk of bladder irritation and bleeding caused by other anti-cancer drugs.

Mesna 200 mg Injection 2 ml contains 'Mesna', a chemo-protectant medicine that alters the breakdown of anti-cancer agents (Ifosfamide) found in the urine, making it less toxic. In addition, it binds to other urotoxic metabolites and inhibits their effects on the bladder.

Mesna 200 mg Injection 2 ml will be administered to your vein by a trained healthcare professional; hence, do not self-administer. In some cases, this medicine may cause certain side effects such as nausea, vomiting, headache, flushing (sense of warmth in the face, ears, neck, and trunk), lethargy, rash, diarrhea, light-headedness, abdominal pain, flu-like symptoms, fever, and injection site reactions. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects are persistent, reach out to your doctor.

Mesna 200 mg Injection 2 ml is not recommended if you are allergic to it or any of its ingredients. An effective birth control measure should be taken to avoid pregnancy in women of a mother-bearing you’re your doctor may suggest regular urine and blood test while receiving Mesna 200 mg Injection 2 ml to monitor your CBC (blood cell count). Mesna 200 mg Injection 2 ml is not indicated for use in hematuria due to other underlying pathological conditions like thrombocytopenia. It is advised to drink at least 1-2 litres of fluid daily while receiving Mesna 200 mg Injection 2 ml. This medicine should be avoided in pregnant and breastfeeding populations due to serious side effects; hence inform your doctor before administration.

Mesna 200 mg Injection 2 ml belongs to a class of medication known as 'chemoprotectant' primarily used to prevent bleeding into the urine by a particular anticancer medicine known as ifosfamide (ifosfamide-induced hemorrhagic cystitis). It also reduces the risk of inflammation and bleeding in the bladder by receiving anti-cancer medication. It contains Mesna, which works by reacting chemically with the urotoxic ifosfamide (anti-cancer medicines) metabolites, resulting in their detoxification. In addition, it binds to other urotoxic metabolites and inhibits their effects on the bladder.

Do not take this injection if you are allergic to Mesna 200 mg Injection 2 ml or any of its ingredients. An effective birth control method should be used to avoid pregnancy in women of childbearing age. Maintain a three-month gap between your last dose of Mesna 200 mg Injection 2 ml and your next pregnancy. Regular urine and blood test should be done while receiving Mesna 200 mg Injection 2 ml to monitor your CBC (blood cell count). It is not indicated for use in hematuria due to other underlying pathological conditions like thrombocytopenia. This medicine is known to cause blurry vision and dizziness, so do not drive or operate machinery. 

• Empty your bladder frequently in the first 24 hours of chemotherapy (cancer treatment). If any pain occurs during urination, let your doctor know it.
• Nausea can occur as a side effect of chemotherapy. Eat small and frequent meals to avoid it, or you can take any anti-nausea medicine.
• Sleep at least 8 hours a day and take plenty of rest.
• Maintain good nutrition. Eat home-cooked and freshly prepared food. Avoid junk, oily and spicy food.

• Regular blood and urine test are required while receiving Mesna 200 mg Injection 2 ml.
• Mesna 200 mg Injection 2 ml may interfere with enzymatic creatinine phosphokinase (CPK) activity tests that use a thiol compound (N-acetylcysteine) for CPK reactivation. This may result in a falsely low CPK level. Inform your doctor about the use of Mesna 200 mg Injection 2 ml.
• Mesna 200 mg Injection 2 ml may interfere with a certain laboratory test (for urinary ketones), possibly causing false test results. Hence inform your doctor or laboratory personnel about the use of this medicine.

Ifosfamide-induced Hemorrhagic cystitis: It is a condition that causes bleeding in the urine due to the effect of anticancer agents (Ifosfamide). It occurs when an individual undergoes planned chemotherapy (for cancer treatment). During chemotherapy, an anticancer medication called 'ifosfamide' causes inflammation and bleeding of the bladder, which is passed into the urine. The colour of urine may vary from pink to red in colour.